Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mindray Medical Nixes Shenzhen IPO; Seeks New Venue

publication date: Feb 28, 2018

Shenzhen Mindray Bio-Medical, a major China medical device maker with operations in the US, has withdrawn its application to IPO on the Shenzhen Stock Exchange. The company did not meet the SSE's balance sheet criteria. Mindray de-listed from the New York exchange in 2016, taken private by its three top executives at a valuation of $3.2 billion. At least one source said Mindray would seek a post-IPO valuation of $15 billion. Mindray will look for another venue, which will probably be Shenzhen's Chi-Next exchange. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital